Advances in the individualized treatment of novel antiepileptic drugs for children

Rui-rui LI,Xiao-yan SHENG,Xia ZHAO,Ying ZHOU,Yi-min CUI
DOI: https://doi.org/10.13286/j.cnki.chinhosppharmacyj.2014.23.28
2014-01-01
Abstract:OBJECTIVE Epilepsy is a chronic disease endangering children's health.To reduce the adverse effects of antiepileptic drugs and improve the treatment and quality of life for patients,individualized drug treatment is needed.METHODS Databases such as CNKI and PubMed were searched to select and organize literatures on methods of individual antiepileptic drug therapy,including the use of saliva substitute blood for therapeutic drug monitoring,the establishment of a population pharmacokinetic model and the use of pharmacogenomics.RESULTS Literatures showed significant correlation between saliva and plasma drug concentrations;population pharmacokinetic model for some new antiepileptic drugs have been successfully established;gene polymorphisms at ABCB1 and ABCC2 loci may be related with drug resistant epilepsy.CONCLUSION It is feasible to use saliva substitute blood for therapeutic drug monitoring;Individualized dosing is becoming possible owing to the successfully established population pharmacokinetic models;the determination of genetic polymorphisms,which has important clinical value,provide the basis for reasonable treatment of drug-resistant epilepsy.
What problem does this paper attempt to address?